All Stories

  1. Safranal-Standardized Saffron Extract Improves Metabolic, Cognitive, and Anxiolytic Outcomes in Aged Mice via Hypothalamic–Amygdalar Peptide Modulation
  2. Long-term Impact of Cenobamate on Cognition in Patients with Drug-Resistant Focal Epilepsy: Outcomes from an Exploratory Real-World Study
  3. Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV‐add study
  4. Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)
  5. Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies
  6. Proposal of an Inflammatory Drug‐Resistant Epilepsy Index (Idrei) as Molecular Composed Biomarker in Focal Epilepsies
  7. Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis
  8. Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy
  9. Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease
  10. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  11. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis
  12. Biomarkers of Neuroinflammation and Epileptogenesis: A Systematic Review
  13. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats
  14. Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus
  15. Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions
  16. Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study
  17. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study
  18. Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol
  19. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
  20. Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies
  21. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  22. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  23. Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
  24. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis
  25. Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
  26. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
  27. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy
  28. Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review
  29. Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis
  30. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  31. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  32. Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
  33. The cognitive and psychiatric subacute impairment in severe Covid-19
  34. Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido probar otro?
  35. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
  36. Prevalence of Neural Autoantibodies in Paired Serum and Cerebrospinal Fluid in Adult Patients with Drug-Resistant Temporal Lobe Epilepsy of Unknown Etiology
  37. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)
  38. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  39. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
  40. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain
  41. Efectos de la pandemia por Covid-19 sobre la calidad de vida de los pacientes con Esclerosis Lateral Amiotrófica
  42. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  43. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis
  44. GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus
  45. Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis
  46. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  47. Emergency implementation of telemedicine for epilepsy in Spain: Results of a survey during SARS-CoV-2 pandemic
  48. Miller‐Fisher syndrome after SARS‐CoV‐2 infection
  49. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases
  50. Reader response: Neurologic complications of coronavirus infections
  51. Ofatumumab versus Teriflunomide in Multiple Sclerosis
  52. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report
  53. Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2
  54. Análisis de letalidad por COVID-19 en pacientes con demencia neurodegenerativa
  55. Incidence and case fatality rate of COVID-19 in patients with active epilepsy
  56. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?
  57. ¿Va a cambiar la neurología tras la pandemia de COVID-19 en los próximos 5 años? Estudio de enfoque mediante informadores clave
  58. Response to immunotherapy in anti‐IgLON5 disease: A systematic review
  59. Evaluación prequirúrgica mediante resonancia magnética funcional en pacientes con tumores neuroepiteliales disembrioplásicos: una serie de casos
  60. Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit
  61. Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene
  62. Miastenia grave inducida por tratamiento con inhibidores del punto de control inmunológico: primer caso secundario a avelumab y revisión de casos previamente publicados
  63. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN
  64. Consenso Delphi EPICON: recomendaciones sobre el manejo adecuado del cambio a acetato de eslicarbazepina en epilepsia
  65. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review
  66. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures
  67. Estudio observacional multicéntrico español sobre el empleo de fármacos antiepilépticos en consultas de neurología
  68. Epidemiología de la epilepsia en España y Latinoamérica
  69. Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients
  70. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
  71. Awagrafia
  72. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
  73. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa
  74. Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study
  75. Adhesión al tratamiento con levetiracetam: estudio observacional retrospectivo no intervencionista
  76. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
  77. Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature
  78. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
  79. Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study
  80. Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015
  81. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study
  82. Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study
  83. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide
  84. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
  85. Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness
  86. Spatial recognition memory in a virtual reality task is altered in refractory temporal lobe epilepsy
  87. The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES)
  88. Validación en castellano de un cuestionario breve útil para cribado epidemiológico de epilepsia en España: Cuestionario EPIBERIA
  89. Acetato de eslicarbazepina en la práctica clínica. Resultados de eficacia y seguridad
  90. Zonisamida en el tratamiento de la epilepsia: revisión de la bibliografía desde la terapia añadida a la monoterapia
  91. Consenso de las Recomendaciones de Actuación diagnóstica y Terapéutica sobre Epilepsia resistente a fármacos antiepilépticos en España (Consenso RATE-España)
  92. Predictive model for refractoriness in Temporal Lobe Epilepsy based on clinical and diagnostic test data
  93. Cajal’s first steps in scientific research
  94. Spatial navigation impairment in patients with refractory temporal lobe epilepsy: Evidence from a new virtual reality-based task
  95. Factores vinculados a la adhesión al tratamiento en pacientes con epilepsia refractaria y no refractaria
  96. Antiepileptic treatment in patients with epilepsy and other comorbidities
  97. Vohwinkel Syndrome secondary to missense mutation D66H in GJB2 gene (connexin 26) can include epileptic manifestations
  98. Amnesia topográfica transitoria: descripción de una serie de ocho casos
  99. Possible case of peripheral osmotic demyelination syndrome
  100. Driving cost factors in adult outpatients with refractory epilepsy: A daily clinical practice in clinics of neurology in Spain
  101. Guía de práctica clínica de la Sociedad Andaluza de Epilepsia sobre profilaxis y tratamiento de las crisis epilépticas sintomáticas agudas
  102. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia sobre prescripción de fármacos antiepilépticos genéricos
  103. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia: recomendaciones terapéuticas ante una crisis epiléptica y en el estado epiléptico
  104. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia para el diagnóstico y tratamiento del paciente con una primera crisis epiléptica en situaciones de urgencia
  105. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)
  106. Possible case of peripheral osmotic demyelination syndrome
  107. Incidencia de ictus en España. Bases metodológicas del estudio Iberictus
  108. Pseudomigraña con pleocitosis y la ‘invisibilidad’ de las descripciones originales en castellano
  109. Clinical Implications of Mechanisms of Resistance to Antiepileptic Drugs
  110. Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS
  111. Bilateral Bell Palsy and Acute HIV Type 1 Infection: Report of 2 Cases and Review
  112. Menstrual Tension-Type Headache: Evidence for Its Existence.
  113. A transcranial doppler study in interictal migraine and tension-type headache
  114. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  115. Encefalomielitis aguda diseminada por picadura de himenóptero
  116. Avances en el conocimiento de la etiología y la fisiopatología de las epilepsias reflejas
  117. Cirugía de la epilepsia del lóbulo temporal: ¿es suficiente eliminar las crisis?
  118. Trombólisis en el ictus: la accesibilidad sin garantía de seguridad es insostenible
  119. Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'
  120. The Red Ear Syndrome: Five New Cases
  121. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica antiepiléptica crónica en el adulto y en el niño
  122. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: III. Tratamiento antiepiléptico en situaciones especiales
  123. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: I. Criterios de inicio y cese y bases farmacológicas del tratamiento antiepiléptico
  124. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: IV. Principios generales de politerapia antiepiléptica y estrategias terapéuticas en epilepsia refractaria
  125. Doppler transcraneal en el diagnóstico de fístula arteriovenosa pulmonar
  126. Infarto maligno de la arteria cerebral media: ¿tratamiento médico o quirúrgico?
  127. Hemorragia cerebral múltiple y antiagregantes plaquetarios
  128. Ring chromosome 20 epilepsy syndrome in children: Electroclinical features
  129. Paciente de 45 años con epilepsia refractaria del lóbulo temporal desde la infancia
  130. Epilepsia refractaria del adulto
  131. Comment: Fluorouracil-Induced Aphasia: Neurotoxicity versus Cerebral Ischemia
  132. Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia
  133. Epilepsia parcial refractaria a tratamiento médico y lesión porencefálica occipital
  134. Controversias en torno a los nuevos fármacos antiepilépticos
  135. El diagnóstico de la enfermedad cervical espondilótica: una revisión basada en la evidencia
  136. Caracterización epidemiológica de la epilepsia del adulto subsidiaria de ingreso hospitalario
  137. Pseudotumor inflamatorio: diagnóstico diferencial de los tumores del IV ventrículo
  138. Cromosoma 20 en anillo: ¿Una canalopatía epiléptica?
  139. Ischemic Stroke following Cisplatin and 5-Fluorouracil Therapy: A Transcranial Doppler Study
  140. Descripción histórica de la asociación de macroorquídia, retraso mental y dismorfia craneal en varones (Síndrome del cromosoma X frágil) por A. B. Richerand
  141. Hemodinámica cerebral en el síndrome de pseudomigraña con pleocitosis de LCR: un estudio Doppler transcraneal
  142. El diagnóstico de la esclerosis temporal mesial mediante imagen de resonancia magnética
  143. Correlación genotipo-fenotipo en la distrofia miotónica y predicción de la gravedad clínica
  144. Hemiatrofia facial progresiva de Parry-Romberg: consideraciones patogénicas y evolutivas a propósito de un caso con seguimiento prolongado
  145. Esclerosis temporal mesial (II): manifestaciones clínicas y estudios complementarios
  146. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases
  147. Mediterranean spotted fever with central and peripheral neurological complications